JP2003508022A - Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法 - Google Patents
Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法Info
- Publication number
- JP2003508022A JP2003508022A JP2001506870A JP2001506870A JP2003508022A JP 2003508022 A JP2003508022 A JP 2003508022A JP 2001506870 A JP2001506870 A JP 2001506870A JP 2001506870 A JP2001506870 A JP 2001506870A JP 2003508022 A JP2003508022 A JP 2003508022A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- allele
- methods
- polymorphic
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 37
- 108010002352 Interleukin-1 Proteins 0.000 title claims abstract description 32
- 201000010099 disease Diseases 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 13
- 102000054766 genetic haplotypes Human genes 0.000 title claims description 15
- 230000002757 inflammatory effect Effects 0.000 title claims description 4
- 108700028369 Alleles Proteins 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000011161 development Methods 0.000 abstract description 2
- 238000003556 assay Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 102000000589 Interleukin-1 Human genes 0.000 description 25
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 13
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000003550 marker Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 102000054765 polymorphisms of proteins Human genes 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000003321 amplification Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 108091008053 gene clusters Proteins 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 4
- 102100039065 Interleukin-1 beta Human genes 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 3
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 3
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010038080 Rectal ulcer Diseases 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 238000010448 genetic screening Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/345,217 | 1999-06-30 | ||
| US09/345,217 US6268142B1 (en) | 1997-05-29 | 1999-06-30 | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
| PCT/US2000/018318 WO2001000880A2 (en) | 1999-06-30 | 2000-06-30 | Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003508022A true JP2003508022A (ja) | 2003-03-04 |
| JP2003508022A5 JP2003508022A5 (enExample) | 2007-09-13 |
Family
ID=23354085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001506870A Pending JP2003508022A (ja) | 1999-06-30 | 2000-06-30 | Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6730476B1 (enExample) |
| EP (1) | EP1194590A2 (enExample) |
| JP (1) | JP2003508022A (enExample) |
| AU (1) | AU784224B2 (enExample) |
| CA (1) | CA2378221A1 (enExample) |
| IL (1) | IL147182A0 (enExample) |
| WO (1) | WO2001000880A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6720141B1 (en) * | 1999-11-01 | 2004-04-13 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for restenosis |
| JP2003508022A (ja) * | 1999-06-30 | 2003-03-04 | インターリューキン ジェネティックス インコーポレイテッド | Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法 |
| WO2002000933A2 (en) * | 2000-06-23 | 2002-01-03 | Interleukin Genetics, Inc. | Screening assays for identifying modulators of the inflammatory or immune responses |
| JP2005500032A (ja) * | 2001-06-15 | 2005-01-06 | インターリューキン ジェネティックス インコーポレイテッド | 老化関連症状の早期発現を検出および治療する方法 |
| AU2002359431A1 (en) | 2001-11-19 | 2003-06-10 | Interleukin Genetics, Inc. | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
| US20080311581A1 (en) * | 2001-11-19 | 2008-12-18 | David Wyllie | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
| US20070264645A1 (en) * | 2002-01-25 | 2007-11-15 | Kenneth Kornman | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| US20050064462A1 (en) * | 2003-06-17 | 2005-03-24 | Bernd Stein | Methods, compositions, and kits for predicting the effect of compounds on hot flash symptoms |
| US20060234274A1 (en) * | 2005-03-29 | 2006-10-19 | Auckland Uniservices Limited | Methods of diagnosis |
| US8105775B2 (en) * | 2005-10-25 | 2012-01-31 | Interleukin Genetics, Inc. | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| CA2668722A1 (en) * | 2006-11-15 | 2008-05-22 | Interleukin Genetics, Inc. | The il-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same |
| WO2009027509A1 (en) | 2007-08-31 | 2009-03-05 | Vestas Wind Systems A/S | Wind turbine siting and maintenance prediction |
| CA2723247A1 (en) * | 2008-05-02 | 2009-11-05 | Interleukin Genetics, Inc. | Detecting genetic predisposition to osteoarthritis associated conditions |
| WO2009142474A1 (en) * | 2008-05-23 | 2009-11-26 | Erasmus University Medical Center Rotterdam | Genetic markers predicting age at menopause |
| ITMI20091054A1 (it) * | 2009-06-15 | 2010-12-16 | Istituto Ortopedico Galeazzi S P A | Metodi per lo screening di polimorfismi genetici associati alla risposta immune per la valutazione della predisposizione atletica e kit relativi |
| US8293753B2 (en) * | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| JP2019503176A (ja) | 2016-01-12 | 2019-02-07 | インターロイキン ジェネティクス， インコーポレイテッド | 処置に対する応答を予測するための方法 |
| US10329620B2 (en) | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| KR102252384B1 (ko) * | 2018-10-08 | 2021-05-14 | 차의과학대학교 산학협력단 | 조기폐경 진단을 위한 분석방법 및 키트 |
| CA3142662A1 (en) | 2019-06-06 | 2020-12-10 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
| WO2021028469A1 (en) | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| IT202000003988A1 (it) * | 2020-02-26 | 2021-08-26 | Allelica S R L | Metodo per una prognosi predittiva dell’insorgenza di menopausa |
| WO2021205013A1 (en) | 2020-04-09 | 2021-10-14 | Sitokine Limited | Compositions and methods for treating covid-19 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998044150A1 (en) * | 1997-03-27 | 1998-10-08 | Gemini Research Ltd. | Polymorphisms of an il-1 receptor antagonist gene |
| WO1998054359A1 (en) * | 1997-05-29 | 1998-12-03 | Gordon Duff | Prediction of inflammatory disease associated with il-1 geneloci polymorphisms |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US5541308A (en) * | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| EP0679196B1 (en) | 1993-01-07 | 2004-05-26 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
| US5593826A (en) | 1993-03-22 | 1997-01-14 | Perkin-Elmer Corporation, Applied Biosystems, Inc. | Enzymatic ligation of 3'amino-substituted oligonucleotides |
| US5698399A (en) * | 1996-04-05 | 1997-12-16 | Duff; Gordon W. | Detecting genetic predisposition for osteoporosis |
| US6210877B1 (en) * | 1997-03-10 | 2001-04-03 | Interleukin Genetics, Inc. | Prediction of coronary artery disease |
| US6720141B1 (en) * | 1999-11-01 | 2004-04-13 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for restenosis |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| US6635418B2 (en) * | 1998-02-13 | 2003-10-21 | Igen International, Inc. | Assay methods for nucleic acid in a sample |
| JP2003508022A (ja) * | 1999-06-30 | 2003-03-04 | インターリューキン ジェネティックス インコーポレイテッド | Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法 |
| EP1212464B1 (en) * | 1999-08-30 | 2006-02-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for osteoporosis |
| JP2005500032A (ja) * | 2001-06-15 | 2005-01-06 | インターリューキン ジェネティックス インコーポレイテッド | 老化関連症状の早期発現を検出および治療する方法 |
| AU2002359431A1 (en) * | 2001-11-19 | 2003-06-10 | Interleukin Genetics, Inc. | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
-
2000
- 2000-06-30 JP JP2001506870A patent/JP2003508022A/ja active Pending
- 2000-06-30 CA CA002378221A patent/CA2378221A1/en not_active Abandoned
- 2000-06-30 AU AU60679/00A patent/AU784224B2/en not_active Expired
- 2000-06-30 EP EP00947005A patent/EP1194590A2/en not_active Withdrawn
- 2000-06-30 IL IL14718200A patent/IL147182A0/xx unknown
- 2000-06-30 WO PCT/US2000/018318 patent/WO2001000880A2/en not_active Ceased
- 2000-08-04 US US09/632,657 patent/US6730476B1/en not_active Expired - Fee Related
-
2004
- 2004-05-03 US US10/838,503 patent/US20050064453A1/en not_active Abandoned
-
2008
- 2008-08-01 US US12/184,786 patent/US20090163460A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998044150A1 (en) * | 1997-03-27 | 1998-10-08 | Gemini Research Ltd. | Polymorphisms of an il-1 receptor antagonist gene |
| WO1998054359A1 (en) * | 1997-05-29 | 1998-12-03 | Gordon Duff | Prediction of inflammatory disease associated with il-1 geneloci polymorphisms |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6067900A (en) | 2001-01-31 |
| EP1194590A2 (en) | 2002-04-10 |
| AU784224B2 (en) | 2006-02-23 |
| CA2378221A1 (en) | 2001-01-04 |
| US20090163460A1 (en) | 2009-06-25 |
| WO2001000880A2 (en) | 2001-01-04 |
| IL147182A0 (en) | 2002-08-14 |
| US20050064453A1 (en) | 2005-03-24 |
| WO2001000880A3 (en) | 2001-11-15 |
| US6730476B1 (en) | 2004-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003508022A (ja) | Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法 | |
| Schultz et al. | Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family | |
| Liu et al. | Mutant fibrillin-1 monomers lacking EGF-like domains disrupt microfibril assembly and cause severe Marfan syndrome | |
| US20060211020A1 (en) | Methods for the diagnosis, prognosis and treatment of metabolic syndrome | |
| JP2002500513A (ja) | ＩＬ−１遺伝子座（ｇｅｎｅｌｏｃｉ）多型性に関連する炎症性疾患の予測 | |
| JP6622731B2 (ja) | 歯周病の重症度および進行を決定するための改良された方法およびキット | |
| Tam et al. | Established and emerging strategies to crack the genetic code of obesity | |
| EP1212464B1 (en) | Diagnostics and therapeutics for osteoporosis | |
| Ganguly et al. | High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families | |
| WO2001016377A9 (en) | Diagnostics and therapeutics for osteoporosis | |
| AU2004263184B2 (en) | Diagnostic and therapeutics for osteoporosis | |
| Castro et al. | Screening of the endothelin1 gene (EDN1) in a cohort of patients with essential left ventricular hypertrophy. | |
| US20090023147A1 (en) | Diagnostics and therapeutics for osteoporosis | |
| US20050233321A1 (en) | Identification of novel polymorphic sites in the human mglur8 gene and uses thereof | |
| KR20050083625A (ko) | 염증성 질환의 판정방법 | |
| JP5644009B2 (ja) | 一塩基多型を用いた炎症性疾患の判定方法 | |
| KR101774996B1 (ko) | 혈우병 치료제의 효능 예측 마커 및 이의 용도 | |
| JP2008502341A (ja) | 電位型カリウムチャネルをコードするヒト肥満感受性遺伝子およびその使用 | |
| Urbanek et al. | The genetics of polycystic ovary syndrome: a model for the analysis of complex genetic diseases | |
| Al-Saud | The genetics of obesity in Saudi Arabian population | |
| JP2007530028A (ja) | ペプチドホルモンをコードするヒト肥満感受性遺伝子及びその使用 | |
| HK1093757B (en) | Diagnostic for osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070702 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070702 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100608 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100908 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100915 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101008 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101018 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101108 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101115 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110215 |